Clinical Trials Directory

Trials / Unknown

UnknownNCT06243263

Postoperative Pain After Bupivacaine Supplementation in Mandibular Fracture Surgery

Postoperative Pain After Bupivacaine Supplementation in Mandibular Fracture Surgery: a Double Blind Controlled Clinical Trial

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
University Tunis El Manar · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Pain following open reduction of mandibular fractures is the most reported complaint during the first 24 post-operative hours. The goal of this clinical trial is to evaluate the impact of inferior alveolar nerve block with bupivacaine 0,5% in patients with mandibular fractures. The main question it aims to answer are: * Does the inferior alveolar nerve block with bupivacaine reduce the intensity of pain after mandibular fracture surgery? * Does the inferior alveolar nerve block with bupivacaine decrease the consumption of analgesics during the first 24 postoperative hours? Participants with bifocal mandibular fractures will be enrolled in the study (a fracture should be located on the dentate portion of the right hemi-mandible, and a second fracture located on the dentate portion of the left hemi-mandible). Each patient will receive either a right or left inferior alveolar nerve block. The patient: * Will be asked to estimate the pain score by the numerical rating scale during the first 24 postoperative hours for each fracture. * They will be given rescue analgesia in case of intense pain. The number of uses of rescue analgesia will be noted. Researchers will compare a group of fracture that will receive the inferior alveolar nerve block with bupivacaine with a group of fracture that will not receive the inferior alveolar nerve block, to see if regional anesthesia improve postoperative pain management of mandibular fractures.

Conditions

Interventions

TypeNameDescription
DRUGBupivacainAt the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.

Timeline

Start date
2024-02-06
Primary completion
2024-03-04
Completion
2024-03-04
First posted
2024-02-06
Last updated
2024-02-14

Locations

2 sites across 1 country: Tunisia

Source: ClinicalTrials.gov record NCT06243263. Inclusion in this directory is not an endorsement.